荣昌生物制药（烟台）股份有限公司 综上，我们同意提名黄国滨先生为公司第二届董事会独立董事候选人，并同 意将该议案提交公司第二届董事会第十七次会议进行审议。 董事会提名委员会 荣昌生物制药（烟台）股份有限公司董事会提名委员会 关于第二届董事会独立董事候选人的审核意见 根据《中华人民共和国公司法》（以下简称"《公司法》"）《上市公司独立董 事管理办法》及《荣昌生物制药（烟台）股份有限公司章程》等有关规定，荣昌 生物制药（烟台）股份有限公司（以下简称"公司"）第二届董事会提名委员会 对第二届董事会独立董事候选人的任职资格进行了审核并发表审核意见如下： 1、经审阅公司第二届董事会独立董事候选人黄国滨先生的个人履历等相关 资料，未发现其存在《中华人民共和国公司法》《上市公司独立董事管理办法》 《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等相关法 律法规、规范性文件以及《公司章程》中规定的不得担任科创板上市公司董事、 独立董事的情形；其最近 36 个月未受过中国证监会、证券交易所及其他有关部 门的处罚和惩戒，亦未有被中国证监会确定为市场禁入者且禁入尚未解除的情 况，不存在因涉嫌犯罪被司法机关立案侦查 ...

证券代码：688331 证券简称：荣昌生物 荣昌生物制药（烟台）股份有限公司 投资者关系活动记录表 | --- | --- | --- | |------------------|---------------------------------------|----------------------------------------------------------------------------------| | | | | | | □ 特定对象调研 | □分析师会议 | | 投资者关系活动 | □ 媒体采访 | 业绩说明会 | | 类别 | □ 新闻发布会 | □路演活动 | | | □ 现场参观 | □ 其他 | | 参与单位名称 | 2024 年三季报业绩说明会 | | | 时间 | 2024 年 12 月 10 日上午 | 10:00-11:00 | | 地点 | 上海证券交易所上证路演中心 | | | | （网址： | http://roadshow.sseinfo.com/ ） | | | 王威东–董事长 | | | | 房健民–总经理 | | | 公司接待人员 | 温庆凯–董事会秘 ...

| 证券代码：688331 | 证券简称：荣昌生物 | 公告编号：2024-051 | | --- | --- | --- | | 港股代码：09995 | 港股简称：榮昌生物 | | 荣昌生物制药（烟台）股份有限公司 关于召开 2024 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2024 年 12 月 10 日(星期二) 上午 10:00-11:00 会议召开地点： 上海证券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 12 月 03 日(星期二) 至 12 月 09 日(星期一)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@remegen.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 三、 参加人员 董事长：王威东先生 总经理：房健民先生 董事会秘书：温庆凯先生 荣昌生 ...

| 证券代码：688331 | 证券简称：荣昌生物 | 公告编号：2024-050 | | --- | --- | --- | | 港股代码：09995 | 港股简称：榮昌生物 | | 关于独立董事辞职的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 鉴于马兰女士辞职将导致公司独立董事人数少于董事会成员的三分之一，根据《中 华人民共和国公司法》《上市公司独立董事管理办法》《上海证券交易所科创板股票上市 规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》以及《公 司章程》等相关规定，其辞职报告将在新的独立董事到任之日或者独立董事人数不少于 公司董事会人数的三分之一起生效，在此之前，马兰女士仍将按照有关法律法规和《公 司章程》的规定继续履行职责。公司将按照相关规定，尽快完成新任独立董事的补选工 作。 马兰女士在担任公司独立董事期间，勤勉尽责、客观独立，在促进公司规范运作等 方面发挥了积极有效的作用，公司及董事会对马兰女士任职期间为公司及董事会工作所 做出的贡献表示衷心感谢！ 特此公告。 荣昌生物制药（烟 ...

Investment Rating - The investment rating for Rongchang Biologics is "Buy" and is maintained [8][6]. Core Views - The company reported a significant narrowing of losses, with Q3 2024 revenue reaching 4.67 billion yuan, a year-on-year increase of 34.6% and a quarter-on-quarter increase of 13.6%. The net profit attributable to the parent company was -2.91 billion yuan, compared to -3.27 billion yuan in Q3 of the previous year [4][5]. - For the first three quarters of 2024, the company achieved a total revenue of 12.09 billion yuan, reflecting a year-on-year growth of 57.1%, while the net profit attributable to the parent company was -10.71 billion yuan, slightly worse than -10.31 billion yuan in the same period last year [4][5]. - The company is making progress in its clinical trials, with RC18 for myasthenia gravis (MG) having its market application accepted and included in the priority review process, potentially leading to approval by the second half of 2025 [5][6]. Financial Performance - In Q3 2024, the company reported a sales expense of 623 million yuan, with a sales expense ratio of 51.5%, down from 52.5% in the first half of 2024. R&D expenses were 1.153 billion yuan, with a ratio of 95.4%, and management expenses were 235 million yuan, with a ratio of 19.4% [4][5]. - The company forecasts net profits for 2024-2026 to be -10.93 billion yuan, -4.58 billion yuan, and 8.19 billion yuan, respectively, with corresponding EPS of -2.01 yuan, -0.84 yuan, and 1.51 yuan [6][10].

Investment Rating - The report maintains a "Buy" rating for the company [3] Core Insights - The company has achieved rapid revenue growth, with a total revenue of 1.209 billion yuan for the first three quarters of 2024, representing a year-on-year increase of 57.10%. The net profit attributable to the parent company was -1.071 billion yuan, a decrease of 3.96% year-on-year [6] - The company’s gross profit margin has significantly improved, reaching 79.75% for the first three quarters of 2024, up by 2.86 percentage points year-on-year. In Q3 alone, the gross profit margin was 82.11%, an increase of 5.86 percentage points year-on-year [6] - The company has a strong cash reserve of approximately 1.12 billion yuan and a loan credit limit of about 2.8 billion yuan, indicating solid financial health [6] Summary by Sections Revenue and Profitability - For Q3 2024, the company reported a revenue of 467 million yuan, a year-on-year increase of 34.60% and a quarter-on-quarter increase of 13.56%. The net profit attributable to the parent company for Q3 was -291 million yuan, showing an 11.08% increase year-on-year and a 32.57% increase quarter-on-quarter [6] - The company’s R&D expense ratio was 95.41% for the first three quarters of 2024, down by 16.09 percentage points year-on-year, while the selling expense ratio was 51.51%, down by 18.64 percentage points [6] Product Development - The NDA for the third indication of Taitasip has been accepted, with the drug now fully approved for SLE in China and undergoing Phase III clinical trials in the US. The drug has also received approval for rheumatoid arthritis in July 2024 and has a listing application for myasthenia gravis accepted in October 2024 [7] - The company is expanding the indications for Vidisizumab in ulcerative colitis (UC), gastric cancer (GC), and breast cancer (BC), with ongoing clinical trials showing positive signals [8] Future Projections - The company is expected to achieve revenues of 1.586 billion yuan, 2.175 billion yuan, and 2.952 billion yuan for 2024, 2025, and 2026 respectively. The net profit attributable to the parent company is projected to be -1.138 billion yuan, -987 million yuan, and -356 million yuan for the same years [8]

1 证券代码：688331 证券简称：荣昌生物 荣昌生物制药（烟台）股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | □ 特定对象调研 | 分析师会议 | | 投资者关系活动 | □ 媒体采访 | □ 业绩说明会 | | 类别 | □ 新闻发布会 | □路演活动 | | | □ 现场参观 | 其他 | | 参与单位名称 | | 华泰证券、海通证券、兴业证券、方正医药、上海博颐投资、东吴证 | | | | 券、东方证券、东海证券、中信资管、中金公司、固禾基金、国泰基 | | | | 金、国金医药、大家资产、摩旗投資、新华资管、景领投资、 ...

Investment Rating - The report does not specify a clear investment rating for the company [1] Core Insights - The company reported a third-quarter revenue of 470 million yuan, representing a year-on-year increase of 34.6% [1] - For the first nine months of 2024, total revenue reached 1.21 billion yuan, up 57.1% compared to the same period last year [1] - The product sales expense ratio for the first nine months was 51.5%, a decrease of 18.6 percentage points year-on-year [1] - The gross profit margin for the first nine months improved to 79.8%, an increase of 2.9 percentage points year-on-year [1] - Research and development expenses in the third quarter amounted to 350 million yuan, a decrease of 26.9% from the second quarter [1] - The net loss for the third quarter was 290 million yuan, a reduction of 32.6% compared to the second quarter [1] Financial Performance - The company is expected to achieve revenues of 1.64 billion yuan, 2.15 billion yuan, and 3.17 billion yuan for the years 2024, 2025, and 2026, respectively [4] - The projected growth rates for revenue are 51.5% in 2024, 31.3% in 2025, and 47.2% in 2026 [4] - The net profit attributable to the parent company is forecasted to be -1.51 billion yuan in 2024, -1.35 billion yuan in 2025, and 561 million yuan in 2026 [4] - The earnings per share (EPS) is expected to be -2.78 yuan in 2024, -2.49 yuan in 2025, -1.00 yuan in 2026, and 1.03 yuan in 2026 [4] - The return on equity (ROE) is projected to improve from -64.94% in 2024 to 26.68% in 2026 [4] Clinical Development - The application for the listing of Taitasip for the treatment of myasthenia gravis was officially accepted in October 2024, following the achievement of primary research endpoints in August 2024 [2] - The company has completed patient enrollment for the phase III clinical trial of Taitasip for Sjögren's syndrome in China and received fast track designation in the U.S. in April 2024 [2] - The phase III clinical trial for IgA nephropathy (IgAN) has also completed patient enrollment [2] - The company is conducting a phase III international multicenter clinical study of Taitasip for systemic lupus erythematosus (SLE) in the U.S. [2] - The company is exploring the use of Vidisizumab for various indications, including HER2-positive breast cancer, with ongoing clinical trials [3]

第一表达在鲁县,在山西这个工作呢已经是目前进入到了数据的期末阶段那么预计呢大概在2025年的第一季度会有数据的特殊阶段的登出这个也就快到了最关键的这是这个2048国内的情况我们海湾呢这个跟辉烈合作那么这个丹药 三药四疗二线的上面的关键临床实验这个实验的辉瑞正在进行推进当中这个BMI的申报时间呢现在要根据现在这个辉瑞将根据一线的三期的进展最终与FDA沟通确认这个申报的时间这个是因为对FDA这些要求呢是对三期 它的进展有联系虽然这个三支的研究呢就是联合匹利物联合资料的一线的尿露双别的三支的研发实验归类有分为这个推举和指导中这个三支的进展呢就是要现在呢就是说说以前比那时明显加快了所以这个时也是一个就是说速度比以前快了 主要是入宿的病人家的意愿明显增加了然后还有一些辉瑞生物科技工作一个是联合突发基尼的资料晚期的颅腺癌和胃癌的二期针对入宿病例另外还有丹药的资料散投颈癌、肥皂细胞皮癌等多数时期有的二期的探测性的工作也针对入宿当中 归类给RC-48的推进方案还是有不少的工作得做那么这是两个商务产品的情况在这一桩实验然后其他的种类产品就是RC-88目前我们在联合RC-88体检秘书把下的AED所以说我们目前其中在联合PTV治疗 ...

Investment Rating - The report maintains a "Hold" rating for Rongchang Biologics with a target price of HKD 26.0 for the Hong Kong stock and RMB 35.0 for the A-share [11][18]. Core Insights - Rongchang Biologics' Q3 2024 revenue met expectations, with a significant improvement in net loss primarily due to effective control of R&D expenses. The company reported a revenue of RMB 470 million, a year-on-year increase of 34.6% and a quarter-on-quarter increase of 13.6% [11][12]. - The gross margin for Q3 2024 was 82.1%, showing a significant year-on-year and quarter-on-quarter improvement, attributed to the economic effect of increased revenue scale [11]. - The management indicated that the sales of Taitasip reached approximately RMB 270 million in Q3 2024, with a 43% year-on-year increase, driven by enhanced market access and recognition of product efficacy [12]. - R&D expenses for Q3 2024 were RMB 350 million, reflecting a 9.3% year-on-year increase but a 26.9% quarter-on-quarter decrease, indicating effective cost management [14]. Financial Summary - For 2024E, the company expects total revenue of RMB 1.769 billion, with a year-on-year growth of 64.4%. The net loss is projected to be RMB 1.34 billion [19]. - The report forecasts a gradual improvement in net loss over the next few years, with estimates of RMB 1.165 billion for 2025E and RMB 816 million for 2026E [18][19]. - The cash and cash equivalents as of September 30 were RMB 1.12 billion, with a loan credit line of RMB 2.8 billion, indicating a solid liquidity position [11].